INCSHR 1210

Drug Profile

INCSHR 1210

Alternative Names: HR-301210; INCSHR1210; SHR1210

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Incyte Corporation; Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatocellular carcinoma
  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Breast cancer; Malignant melanoma

Most Recent Events

  • 25 Apr 2017 Jiangsu HengRui Medicine Co. plans a phase I trial for Nasopharyngeal cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) (NCT03121716)
  • 24 Apr 2017 Jiangsu HengRui Medicine plans a phase II trial for Liver cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) (NCT03092895)
  • 10 Apr 2017 Jiangsu HengRui Medicine plans a phase III trial for Oesophageal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/unresectable) in China (NCT03099382)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top